TMEM106A: A Potential Drug Target Or Biomarker (G113277)

Target Name: TMEM106A

NCBI ID: G113277

TMEM106A

TMEM106A: A Potential Drug Target Or Biomarker

TMEM106A, also known as TMEM106a, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the transmembrane protein family, which means that it spans the cell membrane and extends into the space between cells.

TMEM106A has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern make it an attractive target for researchers to study and potentially develop new treatments.

One of the key features of TMEM106A is its transmembrane nature. This protein is able to interact with both the cytoplasm and the cell membrane, which allows it to play a role in various cellular processes. It is involved in the regulation of cell signaling pathways, and has been shown to interact with a variety of different proteins.

TMEM106A is also known for its role in the regulation of ion and water transport in cells. This protein is involved in the movement of ions and water across the cell membrane, which is critical for maintaining the proper balance of these molecules in the body.

In addition to its role in cell signaling and transport, TMEM106A is also thought to play a role in the development and progression of certain diseases. For example, studies have shown that high levels of TMEM106A are associated with an increased risk of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

TMEM106A is also of interest to researchers because of its expression pattern. Studies have shown that TMEM106A is expressed in a variety of tissues and organs, including the brain, heart, and kidneys. This makes it a potential biomarker for a variety of diseases, as it may be possible to detect changes in the levels of this protein in response to specific therapies.

Another potential use of TMEM106A as a drug target is its role in the regulation of inflammation. This protein has been shown to be involved in the regulation of inflammatory responses, and may play a role in the development of certain inflammatory disorders.

In conclusion, TMEM106A is a protein that is expressed in various tissues of the body, and has been identified as a potential drug target or biomarker for a variety of diseases. Its transmembrane nature and role in cell signaling and transport make it an attractive target for researchers to study, and its expression pattern in various tissues makes it a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of TMEM106A in disease development and progression.

Protein Name: Transmembrane Protein 106A

Functions: Activates macrophages and polarizes them into M1-like macrophages through the activation of the MAPK and NF-kappaB signaling pathway. Upon activation, up-regulates the expression of CD80, CD86, CD69 and MHC II on macrophages, and induces the release of pro-inflammatory cytokines such as TNF, IL1B, IL6, CCL2 and nitric oxide (By similarity). May play a role in inhibition of proliferation and migration (PubMed:30456879, PubMed:29131025)

The "TMEM106A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM106A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets